• 2',7'-Dichlorofluorescein diacetate in Pancreatic Cancer

  2026-09-10

  A translational guide to using 2',7'-Dichlorofluorescein diacetate for intracellular ROS measurement, interpreting redox-responsive nanocarrier studies, and connecting fluorescence signals with tumor penetration, extracellular matrix remodeling, mitochondrial function, and therapeutic decision-making.

• Nicotinamide Riboside Chloride in RGC Translation

  2026-09-09

  Nicotinamide Riboside Chloride (NIAGEN) offers a mechanistically grounded way to examine NAD+ availability alongside reproducible iPSC-derived retinal ganglion cell models. This thought-leadership perspective connects NAD+ biology with dual SMAD and Wnt-controlled differentiation, while separating established evidence from testable translational hypotheses in glaucoma and neurodegenerative disease research.

• ARCA and the Translational Logic of mRNA Therapy

  2026-09-09

  Synthetic mRNA performance is shaped by more than delivery: cap orientation influences translation initiation, RNA persistence, and the amount of therapeutic protein produced per particle. This thought-leadership analysis connects ARCA chemistry with the preclinical stroke study by Gao et al., showing how translational researchers can evaluate capping as a strategic variable without overstating evidence.

• Estradiol Workflows for ER Signaling Research

  2026-09-09

  Build reproducible Estradiol assays that separate ERα, ERβ, autophagy, and downstream transcriptional effects. This practical guide translates new multi-organ evidence into dose planning, controls, readouts, and troubleshooting strategies for cell and translational research.

• Rocilinostat (ACY-1215) HDAC6 Research Workflow

  2026-09-08

  Rocilinostat (ACY-1215) provides a selective way to connect HDAC6 engagement with α-tubulin acetylation, multiple myeloma phenotypes, and proteasome-inhibitor combination responses. This workflow also shows how to examine cilia-related observations without confusing HDAC6 pharmacology with the SMPD4–ceramide mechanism.

• ARL4C, FLS Proliferation, and RA Progression

  2026-09-07

  This study integrates single-cell and bulk RNA sequencing with cellular perturbation, macrophage co-culture, and collagen-induced arthritis modeling to identify ARL4C as a driver of aggressive fibroblast-like synoviocyte behavior in rheumatoid arthritis. Its findings connect ARL4C-dependent synoviocyte proliferation and invasion with macrophage polarization and joint damage, while also defining important boundaries for translational interpretation.

• RG108 DNA Methyltransferase Inhibitor Workflow

  2026-09-07

  RG108 is a non-covalent DNA methyltransferase inhibitor for testing how altered methylation affects gene expression, especially in leukemia and other cancer research models. This workflow combines controlled dosing, locus-focused validation, and troubleshooting strategies to distinguish genuine epigenetic reprogramming from solvent toxicity or nonspecific growth inhibition.

• Caspase-3 Fluorometric Assay Kit Workflow

  2026-09-05

  The Caspase-3 Fluorometric Assay Kit converts DEVD-dependent protease activity into a quantitative AFC fluorescence signal for rapid apoptosis research. Its most useful application is distinguishing caspase-driven apoptosis from ferroptosis-associated stress in RSL3-treated cancer models while supporting orthogonal PARP1 and cell-death analyses.

• Angiotensin I/II (1-5): RAS Workflow Guide

  2026-09-04

  Angiotensin I/II (1-5) provides a defined Asp-Arg-Val-Tyr-Ile peptide fragment for controlled renin-angiotensin system research involving blood pressure regulation and aldosterone signaling. It is not a general-purpose peptide reagent and should not be extended to unrelated signaling assays without independent validation.

• Imipenem Workflow for Antibacterial Research

  2026-09-04

  Imipenem supports more than endpoint susceptibility testing: its PBP-directed activity enables time-resolved bacterial killing, resistance profiling, and carefully controlled immune-cell assays. This workflow connects practical solution handling with translational sepsis animal model design while keeping evidence-backed findings separate from exploratory recommendations.

• IDH1-R132H Autopalmitoylation in Cancer

  2026-09-03

  The reference study identifies C269 autopalmitoylation as a mutation-associated regulatory mechanism that enhances IDH1-R132H activity, dimerization, and oncometabolite production. Its chemoproteomic and functional data connect fatty-acid availability with IDH1-mutant metabolic and epigenetic phenotypes, while also highlighting a hydrophobic pocket with therapeutic relevance.

• Hydroxychloroquine Sulfate Workflow Guide

  2026-09-03

  Hydroxychloroquine Sulfate (SKU B4874) provides an aqueous research reagent for investigating autophagy pathway modulation and TLR7/9-associated responses in autoimmune disease research. It is suited to short-term, water-based workflows, but should not be selected for DMSO- or ethanol-based stocks or long-term storage of prepared solutions.

• Resiquimod (R-848): Reliable Assay Design

  2026-09-02

  This scenario-driven guide shows how Resiquimod (R-848), SKU B1054, can improve experimental clarity in immune-cell viability, proliferation, and cytotoxicity workflows. It covers mechanism, solvent control, preparation, interpretation of combination studies, and practical supplier selection.

• Ivermectin Workflows for Parasitology Research

  2026-09-02

  Build reproducible Ivermectin assays with controlled solvent handling, exposure design, and orthogonal readouts for parasite biology and drug development. A carefully bounded comparison with Gasdermin C research shows how this broad-spectrum anti-parasitic can support exploratory cell-biology workflows without implying an unsupported oncology indication.

• Ceftolozane/Tazobactam: Mechanism and Evidence

  2026-09-01

  The reference review examines ceftolozane/tazobactam as an antipseudomonal cephalosporin and β-lactamase inhibitor designed for resistant gram-negative infections. Its main contribution is an integrated analysis of PBP binding, β-lactamase activity, PK/PD exposure targets, clinical evidence, renal handling, and tolerability.

8626 records 1/576 page Next 12345 下5页 Last page